Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet by 5.05% during Monday's intraday trading session, with shares falling to new lows following a significant price target cut by a major financial institution.

The catalyst for this sharp decline appears to be Mizuho's decision to lower its target price for Apellis Pharmaceuticals from $24 to $19. This represents a substantial 20.8% reduction in the expected value of the stock, signaling decreased confidence in the company's near-term prospects.

While the specific reasons behind Mizuho's target price cut were not immediately clear, such actions by financial analysts often reflect concerns about a company's financial performance, market position, or industry challenges. Investors may interpret this downgrade as a sign to reassess their positions in APLS, potentially leading to increased selling pressure and contributing to the stock's significant intraday decline.